Daniel Castellano
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
Papers in
-
- Renal cell carcinoma treatment 76
- Prostate Cancer Treatment and Research 51
- Oncology 86
- Cancer Immunotherapy and Biomarkers 31
- Pancreatic and Hepatic Oncology Research 22
- Co-authors
- Thomas Powles (27 shared papers)Joaquim Bellmunt (29 shared papers)Elizabeth R. Plimack (9 shared papers)Ronald de Wit (16 shared papers)Ignacio Durán (25 shared papers)Petros Grivas (8 shared papers)Arjun Vasant Balar (9 shared papers)Dean F. Bajorin (6 shared papers)
- Journals
- Annals of Oncology (47 papers)European Urology (20 papers)European Journal of Cancer (17 papers)Journal of Clinical Oncology (14 papers)Clinical Genitourinary Cancer (12 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Daniel Castellano
310 papers receiving 31.4k citations
Daniel Castellano's Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 13.3k
- Pulmonary and Respiratory Medicine 11.8k
- Cancer Research 4.0k
- Surgery 7.9k
- Immunology 3.1k
Countries citing papers authored by Daniel Castellano
This map shows the geographic impact of Daniel Castellano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Castellano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Castellano more than expected).
Fields of papers citing papers by Daniel Castellano
This network shows the impact of papers produced by Daniel Castellano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Castellano. The network helps show where Daniel Castellano may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Castellano, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 316 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 3 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 3043 |
| 4 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 5 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Hit paper breakdown → | 2020 | 1331 |
| 6 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1141 |
| 7 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 1080 |
| 8 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 876 |
| 9 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 609 |
| 10 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 Hit paper breakdown → | 2017 | 554 |
| 11 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 12 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Hit paper breakdown → | 2021 | 495 |
| 13 | Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 478 |
| 14 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 457 |
| 15 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Hit paper breakdown → | 2020 | 410 |
| 16 | 2010 | 348 | |
| 17 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 18 | 2017 | 286 | |
| 19 | 2020 | 247 | |
| 20 | 2017 | 227 |
About Daniel Castellano
Daniel Castellano is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Epidemiology, having authored 316 papers that have together received 32.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (91 papers), Renal cell carcinoma treatment (76 papers), Prostate Cancer Treatment and Research (51 papers), Cancer Immunotherapy and Biomarkers (31 papers), Cancer Genomics and Diagnostics (29 papers), Neuroendocrine Tumor Research Advances (29 papers), Urinary and Genital Oncology Studies (23 papers) and Pancreatic and Hepatic Oncology Research (22 papers). The work is most often cited by research in Oncology (13.3k citations), Pulmonary and Respiratory Medicine (11.8k citations), Cancer Research (4.0k citations), Surgery (7.9k citations) and Immunology (3.1k citations). Daniel Castellano has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Thomas Powles, Joaquim Bellmunt, Elizabeth R. Plimack, Ronald de Wit, Ignacio Durán, Petros Grivas, Arjun Vasant Balar, Dean F. Bajorin, Jacqueline Vuky and Peter H. O’Donnell. Their work appears in journals such as Annals of Oncology, European Urology, European Journal of Cancer, Journal of Clinical Oncology and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.